These non-acute MNs have also been regarded as early stage AML [12], due to a mutational profile with fewer myelodysplasia-related gene mutations [5,6], their sensitivity to chemotherapy, the eradication of NPM1 following intensive treatment and its reappearance at relapse [5,6]. The gene discussed is NPM1; the disease is Myelodysplasia.